Date: 2016-08-10
Type of information: Nomination
Compound:
Company: Kuros Biosciences (Switzerland)
Therapeutic area: Regenerative Medicine
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 10, 2016, Kuros Biosciences announced that Dr. Philippe Saudan has been appointed Chief Development Officer and member of the Executive Board with immediate effect. Dr. Saudan has spent the last 16 years in the pharmaceutical industry and has held different management roles in research and development (R&D). He has considerable experience in R&D and international project management of multidisciplinary programs. In his last position, he served as Chief Scientific Officer of Cytos Biotechnology, where he worked at the interface between pre-clinical research, manufacturing and development of several clinical projects. Since February 2016, Dr. Saudan has been working as Head of Integration of Kuros Biosciences. In this position, he has been closely involved in the different development programs in tissue repair and regeneration. Dr. Saudan holds a PhD in biology?from the University of Lausanne, Switzerland. ? Last January, Kuros Biosciences has closed the acquisition of Kuros Biosurgery Holding Ltd. and the change of name of the combined company to Kuros Biosciences.
Financial terms:
Latest news:
